文献速递免疫规划

随机、双盲、安慰剂对照3期试验证明Butantan-登革疫苗简化配方3个批次间的一致性

Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.
PubMed 文献 · Vaccine · 2025-10-14

在巴西南部非流行区两个研究中心纳入700名18至59岁、无登革热暴露史的受试者,按2:2:2:1随机分配接受三个批次的简化配方Butantan-登革疫苗或安慰剂。接种后第28天用病毒减少中和试验检测四个登革病毒血清型的中和抗体,以几何平均滴度比值的95%CI在>1/2且<2.0内为批次一致性标准;12个两两比较中10个达到等效标准、2个边缘未达到,疫苗相关不良事件总体频率为Butantan-DV组90.8%(544/599) vs 安慰剂组76%(76/100)。

要点

  • 三个批次简化配方Butantan-DV在12个批次与血清型两两比较中10个达到等效标准,2个边缘未达到。
  • 疫苗相关不良事件总体频率为Butantan-DV组90.8%(544/599) vs 安慰剂组76%(76/100)。
  • 作者结论认为三个批次简化配方安全并达到批次等效终点。

核心结论

  • 作者认为简化配方三个批次安全并达到批次等效终点。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验,在巴西南部非流行区两个研究中心纳入700名18至59岁、无登革热暴露史受试者,按2:2:2:1平行分配接受三个批次简化Butantan-DV或安慰剂。
  • 接种后第28天以病毒减少中和试验(VRNT60)检测四个登革病毒血清型的中和抗体,符合方案集607人(86.7%)用于批次一致性分析。
  • 试验注册号ClinicalTrials.gov NCT02406729。

主要发现

  • 2022年11月4日至2023年1月16日随机并接种700人,607人(86.7%)纳入符合方案集。
  • 三个批次与四个血清型的12个两两比较中,10个达到批次等效终点,2个边缘未达到。
  • 疫苗相关不良事件总体频率为Butantan-DV组90.8%(544/599) vs 安慰剂组76%(76/100)。

关键数值与推荐

  • 批次一致性标准为符合方案集中三个批次与四个血清型共12个两两比较的几何平均滴度(GMT)比值双侧95%CI均在>1/2且<2.0的等效范围内。
  • 12个两两比较中10个达到等效标准,2个边缘未达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Background We aimed to evaluate the consistency of the immune response on Day 28 postvaccination with three consecutive lots of simplified formulation of Butantan-Dengue Vaccine (Butantan-DV) and to describe the frequency of vaccine-related adverse events from vaccination through Day 21 postvaccination in comparison to placebo. METHODS: We included 700 participants allocated in a ratio 2:2:2:1 in parallel arms to receive any of three lots of simplified Butantan-DV or placebo, aged 18 to 59 years, without previous exposure to dengue in two study sites from a non-endemic area in Southern of Brazil. The consistency of three lots of the Butantan-DV were evaluated by analyzing the serum neutralizing antibody titers against four dengue virus serotypes by virus reduction neutralization test (VRNT60), on the Day 28 post-vaccination. Criterion for lot-to-lot consistency was two-sided 95 % confidence interval (95 % CI) of geometric mean titers (GMT) ratio within the margins of equivalence of >1/2 and < 2.0 for 12 possible pairwise comparison for the three lots and four serotypes in the Per-Protocol Set. Adverse events were analysed according to the frequency and Miettinen & Nurminen method to build 95 % CI for the difference in the binomial proportions of each lot with the placebo group. This trial is registered with ClinicalTrials.gov, NCT02406729. FINDINGS: Between November 4th, 2022 and January 16th, 2023, 700 participants were randomized and vaccinated, while 607 (86.7 %) were included in the Per-Protocol Set. From the 12 possible pairwise comparison between three lots and four serotypes of DENV, 10 met the endpoint of equivalence of lots and 2 failed marginally. The overall frequency of vaccine-related adverse events was 90.8 % (544/599) in Butantan-DV group and 76 % (76/100) in placebo group. INTERPRETATION: Three lots of simplified formulation were safe and achieved the endpoint of equivalence of lots. FUNDING: Intramural Research Program US NIH National Institute of Allergy and Infectious Diseases, Brazilian National Bank for Economic and Social Development, and Fundação Butantan.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Peixoto de Miranda ÉJF, de Sousa Moreira JA, da Silva Braga R, et al. Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine. Vaccine. 2025. PMID: 41092804. doi:10.1016/j.vaccine.2025.127836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。